These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6763540)

  • 21. Anti-host cytotoxic T cells of bone marrow transplant recipients with or without graft-versus-host disease are equally sensitive to cyclosporin A.
    Liem LM; van Noort JT; Goulmy E
    Bone Marrow Transplant; 1996 Jul; 18(1):73-8. PubMed ID: 8831998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerance induction in clinical transplantation.
    Fehr T; Sykes M
    Transpl Immunol; 2004; 13(2):117-30. PubMed ID: 15380542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of cyclosporin A (CsA) in a rat model of allogeneic marrow transplantation.
    Tutschka PJ; Beschorner WE; Hess AD
    Haematol Blood Transfus; 1980; 25():241-53. PubMed ID: 7021342
    [No Abstract]   [Full Text] [Related]  

  • 26. [Cyclosporin: experimental studies and clinical use in organ transplants].
    Araujo JL; Towpik E; Kupiec-Weglinski JW; Tilney NL
    Rev Invest Clin; 1984; 36(4):367-76. PubMed ID: 6396785
    [No Abstract]   [Full Text] [Related]  

  • 27. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy.
    Wu T; Sozen H; Luo B; Heuss N; Kalscheuer H; Lan P; Sutherland DE; Hering BJ; Guo Z
    Bone Marrow Transplant; 2002 Jun; 29(12):949-56. PubMed ID: 12098061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pathways in the development of transplantation pharmacology].
    Shumakov VI; Seĭfulla RD
    Farmakol Toksikol; 1977; 40(6):656-67. PubMed ID: 23309
    [No Abstract]   [Full Text] [Related]  

  • 30. Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation.
    Mathew JM; Garcia-Morales RO; Carreno M; Jin Y; Fuller L; Blomberg B; Cirocco R; Burke GW; Ciancio G; Ricordi C; Esquenazi V; Tzakis AG; Miller J
    Transpl Immunol; 2003; 11(3-4):307-21. PubMed ID: 12967784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.
    Glass B; Uharek L; Gaska T; Gassmann W; Löffler H; Müller-Ruchholtz W
    Bone Marrow Transplant; 1993; 12 Suppl 3():S41-7. PubMed ID: 8124257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current aspects in organ transplantation].
    Ryffel B
    Schweiz Rundsch Med Prax; 1989 Sep; 78(37):997-1002. PubMed ID: 2678372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The beginning of clinical tolerance in solid organ allografts.
    Monaco AP
    Exp Clin Transplant; 2004 Jun; 2(1):153-61. PubMed ID: 15859922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of cytotoxic effector cell function in patients with leukemia or aplastic anemia before and after marrow transplantation.
    Livnat S; Seigneuret M; Storb R; Prentice RL
    J Immunol; 1980 Jan; 124(1):481-90. PubMed ID: 6765970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunosuppression and the problems in homologous bone marrow transplantation].
    Yabe H; Kato S
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):681-2. PubMed ID: 8963784
    [No Abstract]   [Full Text] [Related]  

  • 38. B7.2-/- mature dendritic cells generate T-helper 2 and regulatory T donor cells in fetal mice after in utero allogeneic bone marrow transplantation.
    Bhattacharyya S; Cowan MJ
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):657-71. PubMed ID: 16125636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sca1(+)/Mac1(+) nitric oxide-producing cells in the spleens of recipients early following bone marrow transplant suppress T cell responses in vitro.
    Johnson BD; Hanke CA; Becker EE; Truitt RL
    Cell Immunol; 1998 Nov; 189(2):149-59. PubMed ID: 9790729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.